Welcome to Shanghai Probechem Biochemicals Co Ltd !Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : Ilorasertib
CAS No.: 1227939-82-3
Catalog No.: PC-21147Not For Human Use, Lab Use Only.
Ilorasertib (ABT-348) is a potent inhibitor of Aurora kinases as well as the VEGF and PDGF families of receptor tyrosine kinases (Aur B IC50=2 nM, PDGFRβ IC50=3 nM).
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 5 mg | $228 | In stock | |
| 10 mg | $378 | In stock | |
| 25 mg | $588 | In stock | |
| 100 mg | Get quote | ||
| 1 g | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Ilorasertib (ABT-348) is a potent inhibitor of Aurora kinases as well as the VEGF and PDGF families of receptor tyrosine kinases (Aur B IC50=2 nM, PDGFRβ IC50=3 nM).
Ilorasertib (ABT-348) inhibits phosphorylation of histone H3, induces of polyploidy, and inhibits proliferation of a variety of leukemia, lymphoma, and solid tumor cell lines (IC(50) = 0.3-21 nM).
Ilorasertib (ABT-348) shows potent binding activity (K(i) < 30 nM) against VEGFR/PDGFR families and the Src family of cytoplasmic tyrosine kinases.
Ilorasertib (ABT-348) inhibits VEGFR/PDGFR autophosphorylation in cells and inhibition of VEGF-stimulated endothelial cell proliferation (IC(50) ≤ 0.3 nM).
Ilorasertib (ABT-348) exhibits antiproliferative activity against BCR-ABL chronic myeloid leukemia cells and cells expressing the gleevec-resistant BCR-ABL T315I mutation.
Ilorasertib (ABT-348) demonstrates significant antitumor efficacy in representative solid tumor [HT1080 and pancreatic carcinoma (MiaPaCa), tumor stasis] and hematological malignancy (RS4;11, regression) xenografts.
| M.Wt | 488.54 | |
| Formula | C25H21FN6O2S | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
N-[4-[4-Amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl]phenyl]-N′-(3-fluorophenyl)urea |
|
1. Glaser KB, et al. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
2. Curtin ML, et al. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4750-5.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
